Catalyst Biosciences to Present at H.C. Wainwright & Co. 20th Annual Global Investment Conference
August 30 2018 - 8:00AM
Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage
biopharmaceutical company focused on developing novel medicines to
address hematology indications, today announced that Nassim Usman,
Ph.D., president and chief executive officer of Catalyst
Biosciences, will present at the H.C. Wainwright & Co. 20th
Annual Global Investment Conference at 3:50 p.m. EDT on Wednesday,
Sept. 5, 2018 at the St. Regis, New York.
A copy of presentation materials can be accessed by visiting the
Events and Presentations section of the Catalyst website after the
presentation concludes.
About Catalyst BiosciencesCatalyst is a
clinical-stage biopharmaceutical company developing novel medicines
to address hematology indications. Catalyst is focused on the field
of hemostasis, including the subcutaneous prophylaxis of hemophilia
and facilitating surgery in individuals with hemophilia. For more
information, please visit www.catalystbiosciences.com.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties. Forward-looking statements include statements
about the potential for Catalyst’s product candidates, including
its subcutaneously administered product candidates, to address
hemophilia indications, and its plans to advance these product
candidates. Actual results or events could differ materially from
the plans, intentions, expectations and projections disclosed in
the forward-looking statements. Various important factors could
cause actual results or events to differ materially from the
forward-looking statements that the Company makes, including, but
not limited to, the risk that trials and studies may be delayed and
may not have satisfactory outcomes, that human trials will not
replicate the results from animal studies, that potential adverse
effects may arise from the testing or use of the Company’s
products, including the generation of antibodies, the risk that
costs required to develop or manufacture the Company’s products
will be higher than anticipated, competition and other factors that
affect our ability to establish collaborations on commercially
reasonable terms and other risks described in the “Risk Factors”
section of the Company’s Annual Report on Form 10-K for the year
ended December 31, 2017 along with other filings with the
Securities and Exchange Commission. The Company does not assume any
obligation to update any forward-looking statements, except as
required by law.
Contacts
Investors:
Fletcher Payne,
CFO
Catalyst Biosciences,
Inc.
1.650.871.0761
investors@catbio.com
Media:Josephine Belluardo, Ph.D.LifeSci Public
Relations1.646.751.4361jo@lifescipublicrelations.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024